

*Sub 32*  
*E2* 2. (Amended) The antagonist molecule according to Claim 1, wherein said amino acid modification is a substitution of said at least one cysteine residue with a different amino acid which is incapable of participating in a disulfide bond, wherein said different amino acid residue is not serine.

*Sub 33*  
*E3* 4. (Amended) The antagonist molecule according to Claim 2 wherein aspartic acid is substituted for cysteine.

5. The antagonist molecule according to Claim 4 comprising the substitution C51D.
6. The antagonist molecule according to Claim 4 comprising the substitution C60D.
7. The antagonist molecule according to Claim 1 wherein said amino acid modification is a chemical modification of said at least one cysteine residue which renders said cysteine residue incapable of participating in a disulfide bond.
10. An isolated nucleic acid sequence comprising a sequence that encodes the VEGF antagonist molecule of Claim 1.
11. A replicable expression vector capable in a transformant host cell of expressing the nucleic acid of Claim 10.
12. Host cells transformed with the vector according to Claim 11.
13. Host cells according to Claim 12 which are Chinese hamster ovary cells.
14. A composition of matter comprising the VEGF antagonist molecule according to Claim 1 compounded with a pharmaceutically acceptable carrier.